Recent Updates
Recently added Catalysts
OFIX Positive Sentiment

Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance

Monday, November 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Orthofix Medical Inc. reported its financial results for Q3 2026, showing net sales of $207.9 million, a 1% increase. The company also revised its full-year 2026 guidance for net sales and non-GAAP adjusted EBITDA. The pro forma results exclude the discontinued M6 product lines.

Market Sentiment Analysis

POSITIVE FACTORS

  • Total reported net sales increased by 1%.
  • Revised full-year guidance indicates positive expectations.

Full Press Release Details

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported financial results for the third quarter ended September 30, 2026, and revised its full-year 2026 net sales and non-GAAP adjusted EBITDA guidance. Unless otherwise noted, pro forma results exclude the impact of the discontinued M6™ product lines. Third Quarter 2026 Highlights Total reported net sales of $207.9 million, representing an increase of 1% on a reported b

Frequently Asked Questions

What were Orthofix's Q3 2026 net sales?

Orthofix reported net sales of $207.9 million for Q3 2026.

How much did net sales increase in Q3 2026?

Net sales increased by 1% compared to the previous period.

What guidance did Orthofix revise?

Orthofix revised its full-year 2026 net sales and EBITDA guidance.

What product lines were excluded from the results?

The results exclude the impact of the discontinued M6 product lines.

ShareAdd on Google
Tags: OFIX Orthofix Q3 2026 net sales guidance
Last updated: Nov 9, 2026

Biotech snapshot

Cash runway
$104M liquidity · $2M/mo burn
~47 mo
Minimal dilution risk